关键词检索
按:
检索词:
  高级检索
引用:余进海,戴德泉,张萍,廖洪斐,秦瑶,王耀华.利妥昔单抗对中重度甲状腺相关眼病疗效的Meta分析.国际眼科杂志 2020;20(8):1379-1383,doi:10.3980/j.issn.1672-5123.2020.8.18
利妥昔单抗对中重度甲状腺相关眼病疗效的Meta分析
Meta-analysis of the efficacy of Rituximab in thyroid associated ophthalmopathy
投稿时间:2020-01-16  修订日期:2020-06-30
Email this Article  Add to Favorite  Print
DOI:10.3980/j.issn.1672-5123.2020.8.18
关键词:  甲状腺相关性眼病  治疗  利妥昔单抗  临床活动评分  Meta分析
Key Words:  thyroid associated ophthalmopathy  therapy  rituximab  clinical activity score  Meta-analysis
基金项目:
Fund Project:
                 
作者单位
余进海 中国江西省南昌市,南昌大学附属眼科医院眼眶病科
戴德泉 中国江西省乐平市人民医院内分泌科
张萍 中国江西省九江市柴桑区人民医院五官科
廖洪斐 中国江西省南昌市,南昌大学附属眼科医院眼眶病科
秦瑶 中国江西省南昌市,江西省儿童医院内分泌遗传代谢科
王耀华 中国江西省南昌市,南昌大学附属眼科医院眼眶病科
                 
AuthorInstitution
Jin-Hai Yu Department of Orbital Diseases, Eye Hospital Affiliated to Nanchang University, Nanchang , Jiangxi Province, China
De-Quan Dai Department of Endocrinology, People's Hospital of Leping City, Leping , Jiangxi Province, China
Ping Zhang Department of Otolaryngology, Chaisang District People's Hospital, Jiujiang , Jiangxi Province, China
Hong-Fei Liao Department of Orbital Diseases, Eye Hospital Affiliated to Nanchang University, Nanchang , Jiangxi Province, China
Yao Qin Department of Endocrine Genetics and Metabolism, Children's Hospital of Jiangxi Province, Nanchang , Jiangxi Province, China
Yao-Hua Wang Department of Orbital Diseases, Eye Hospital Affiliated to Nanchang University, Nanchang , Jiangxi Province, China
摘要点击次数: 88
Hits:
全文下载次数: 34
Download times:
摘要:
      

目的:通过文献荟萃分析评价利妥昔单抗治疗中重度甲状腺相关眼病的疗效。

     方法:检索中国知网(CNKI)、万方、维普、中国生物医学、PubMed、Web of Science、OVID、Corhone Library、ClinicalTrial.gov等数据库从建库至2019-12-31发表的关于利妥昔单抗治疗中重度甲状腺相关眼病的临床研究。以治疗前后甲状腺相关眼病的临床活动评分为疗效的主要判定指标。将检索到的文献应用RevMan 5.3统计学软件进行分析。

     结果:纳入了6项研究61例患者,其中2项为随机对照试验,4项为队列研究。Meta分析显示,应用利妥昔单抗治疗中重度甲状腺相关眼病,可使患者的临床活动评分显著降低\〖SMD=-5.04,95%CI(-7.08~-3.01),P<0.00001\〗。

     结论:利妥昔单抗可使中重度甲状腺相关眼病患者的临床活动评分显著下降,对疾病的控制有良好效果。

Abstract:
      AIM: To evaluate the efficacy of rituximab in thyroid associated ophthalmopathy by using a Meta-analysis of the literature.

     METHODS: Databases such as CNKI, Wanfang, Weipu, China Biomedical, PubMed, Web of Science, OVID, Cochrane Library, and ClinicalTrial.gov were searched. From the establishment of the database to December 31, 2019 on rituximab clinical studies on the treatment of thyroid associated ophthalmopathy. The clinical activity score of thyroid associated ophthalmopathy before and after treatment was used as the main judgment index of curative effect. The retrieved clinical studies were analyzed using RevMan 5.3 statistical software.

     RESULTS: Six studies were included, two were randomized controlled trials, and four were cohort studies. Meta analysis showed that the application of rituximab in the treatment of moderate to severe thyroid associated ophthalmopathy can significantly reduce the clinical activity score of patients, and has statistical significance \〖SMD=-5.04, 95% CI(-7.08 to -3.01), P<0.00001\〗.

     CONCLUSION: Rituximab can significantly reduce the clinical activity score of patients with moderate to severe thyroid associated ophthalmopathy, and has a good effect on disease control.

Citation Html:
附件
查看全文PDF FullText  查看/发表评论  下载PDF阅读器